Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25208892 | 1.00 | P2RY10 (0.47) | P2RY10USP2HTTLPAR1LPAR3 | |
| SCHEMBL2217519 | 1.00 | P2RY10 (0.47) | P2RY10USP2HTTLPAR1LPAR3 | |
| SCHEMBL2231310 | 1.00 | P2RY10 (0.47) | P2RY10USP2HTTLPAR1LPAR3 | |
| SCHEMBL1967093 | 1.00 | P2RY10 (0.47) | P2RY10USP2HTTLPAR1LPAR3 | |
| SCHEMBL17445655 | 0.93 | CASR (0.43) | P2RY10USP2LPAR1LPAR3PLA2G2A | |
| SCHEMBL25243275 | 0.93 | USP2 (0.50) | USP2HTTLPAR5CTSKPLA2G2A | |
| SCHEMBL25289434 | 0.93 | USP2 (0.50) | USP2HTTLPAR5CTSKPLA2G2A | |
| SCHEMBL2220171 | 0.93 | USP2 (0.50) | USP2HTTLPAR5CTSKPLA2G2A | |
| SCHEMBL25289433 | 0.93 | USP2 (0.50) | USP2HTTLPAR5CTSKPLA2G2A | |
| SCHEMBL1965094 | 0.93 | USP2 (0.50) | USP2HTTLPAR5CTSKPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177156-A1 | Sterol-Modified Amphiphilic Lipids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177156-A1 | Sterol-Modified Amphiphilic Lipids | SREBF1, SREBF2, SGMS1 | P2RY10 4781/4885USP2 2160/4885HTT 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.